5:28 PM
 | 
Apr 17, 2013
 |  BC Extra  |  Top Story

FDA panel backs Breo for COPD

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 9-4 that efficacy and safety data for Breo fluticasone furoate/vilanterol from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) support approval of the combination product as a maintenance therapy for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >